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INTRODUCTION
The protease inhibitor (PI) darunavir, boosted by ritonavir (DRV/r), has significant activity against both wild-type and multidrug-resistant HIV-1 strains in adults [1] [2] [3] , and is virologically effective and generally well tolerated in PI-experienced children [4] . Currently, lopinavir (LPV/r) is the preferred first PI in children in Europe [5] and US [6] , largely because it is the only coformulated PI, and is licensed for all ages and weights in tablet and syrup formulations. DRV/r is licensed in children aged ≥6 years as a twice-daily tablet [7] while 24-week data on the safety and efficacy of a DRV/r suspension in 3-6 year olds (ARIEL, NCT0091985) [8] recently found DRV/r to be effective in this group with no additional safety findings. A once-daily dosing study (NCT00915655) is ongoing. In the future, a co-formulation of DRV with a PI booster might increase its clinical utility.
Regarding resistance, the presence of ≥3 DRV resistance-associated mutations (RAMs) at baseline has been associated with diminished virological response to DRV/r in the POWER [9] and DUET [10] trials in adults. However, in another adult study of ~232,000 resistance tests on clinical samples (with unknown ART history) from [2003] [2004] [2005] [2006] [2007] [2008] [2009] , only 3% of patients had ≥2 DRV RAMs and 94% harboured none [11] , with the prevalence of RAMs having decreased over time. In the ARIEL trial, 2 children with one or two DRV RAMs at baseline had HIV-RNA <50c/ml at 24 weeks [8] . Conversely, the protease mutation V82A has been linked to improved response to DRV/r in adults with multiple DRV RAMs [12] .
As DRV/r may be used more frequently in children in the future, as first PI and/or as second PI after previous PI failure (most likely following LPV/r), estimating the prevalence of RAMs in children is important to ascertain its potential clinical utility in this population.
METHODS
Details of the Collaborative HIV Paediatric Study (CHIPS) have been published elsewhere [13] .
Briefly, HIV-infected children born in the UK or Ireland or presenting to health services are reported to the National Study of HIV in Pregnancy and Childhood and followed up in CHIPS.
CHIPS is linked on an annual basis to the UK HIV Drug Resistance Database, a central repository for resistance tests performed as part of routine care throughout the UK; most of these (~90%) tests are viral gene sequences. Resistance data for this analysis were available to the end December 2008. All three studies have research ethics committee approval.
Mutations associated with resistance to DRV were identified from IAS 2010 [14] (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V), a list of RAMs updated by the IAS Drug Resistance Mutations Group using published or presented study data. Additional mutations were identified from the Stanford database (I47A, G73S/T/C, I84A/C, V82F), Stanford University, US, which links HIV reverse transcriptase and protease sequences to individual drug-treatment histories and drug susceptibility data. As V82A has been associated with an increased susceptibility to DRV/r [11] , it was considered in additional analyses.
The prevalence of DRV RAMs was calculated in PI-naive children (on other combination antiretroviral therapy (ART) or ART-naive) using the first available resistance test for each child prior to PI use to evaluate the extent of transmitted drug resistance and the potential use of DRV as a first PI. In PI-experienced children, cumulative resistance [15] at the last available test on PI, before any use of darunavir, was calculated to evaluate the prevalence of resistance to DRV as a subsequent PI. Multivariate Poisson regression with backwards elimination (exit p=0.10) was used to examine associations between the number of RAMs and years on a PI, area under the log viraemia curve (time-averaged, censoring at <400 copies/ml as <50 copies/ml assays were not always used), and type of PI, adjusting for sex, ethnicity, place of birth, and age and disease parameters at presentation and resistance test. In addition, susceptibility to DRV was assessed using the Stanford database algorithm which classifies individual drug resistance as susceptible, potential low-level, low-level, intermediate, or high, based on viral gene sequences.
RESULTS
1,485 UK children were followed in CHIPS during 1998-2008. 1,406 were PI-naïve at the start of the study period or at entry into CHIPS if later than 1 st January 1998, of whom 417(30%) had a PI-naïve resistance test. 1,154(78%) UK children had taken ART between 1998 and 2008 inclusive. Of these, 620(54%) had taken a PI, most commonly LPV/r (442, 71%) or nelfinavir (NFV 271, 44%), and less frequently DRV/r (15, 2%: 5 once-daily).177 of the 620(29%) had a resistance test whilst on a PI, but before the use of DRV if ever taken.
Demographics and immunological and virological parameters at the time of the first available test for PI-naive children, and last test for PI-experienced children, are presented in Table 1 .
PI-experienced children were older at their last test than PI-naive children at their first test and a higher proportion had progressed to CDC stage C.
The type and number of DRV RAMs in PI-naïve and PI-experienced (split by LPV/r only vs.
other) children are presented in Table 2 . No PI-naïve child had more than one DRV RAM.
Only 3 (4%) children who had taken LPV/r as their only PI had 1 RAM while 16 (15%) children with other PI exposure had 1 RAM and 7 (6%) had 2 RAMs. Only two PI-experienced children had accumulated ≥3 IAS DRV RAMs. One child with 3 RAMs had been exposed to NFV and amprenavir for 8 months without virological suppression and one child with 4 RAMs had been exposed to NFV, amprenavir, and indinavir for 26 months and suppressed their viral load <400 copies/ml for only 4 months. The majority of IAS DRV RAMs were accumulated by the time of the first test on a PI, when 18 children had one, and one had two, mutations.
PI-experienced children had spent a median (IQR) 2.7 (1.1-5.2) years on PIs, with a median (IQR) time-averaged area under the log viraemia curve on PIs of 3.4 (2.8-3.9) copies/ml. Using the Stanford algorithm, only six PI-experienced children had intermediate level resistance
to DRV and none had high-level resistance. Five of these had 2 IAS DRV RAMs (1 with an additional Stanford mutation) and one had 4. All six children had prior exposure to LPV/r and NFV with four also having at least two other prior PIs (including amprenavir, indinavir, ritonavir, saquinavir, and tipranavir). None had been virologically suppressed on a PI with PI exposure ranging from 2.5-8 years. A further 12 children had low-level resistance and 10 had possible low-level resistance.
An analysis of predictors of susceptibility, as predicted by Stanford, was consistent with the analysis of predictors of the number of DRV RAMs. Susceptibility reduced with increasing time on PIs (8/96 (8%) children with <3 years PI exposure had possible low-level or higher level resistance vs. 20/81 (25%) with 3+ years, chi 2 p=0.003), a greater area under the viraemia curve (17/141 (12%) children with <4 log 10 copies/ml had low or higher-level resistance vs.
11/35 (31%) with 4+ log 10 copies/ml, p=0.005), and previous PI limited to LPV/r (0/69 (0%) 8 children on LPV/r only had potential low-level or higher resistance in comparison to 28/108 (26%) of those with other PI, or multiple PI, experience, p<0.001).
DISCUSSION
Ritonavir-boosted darunavir has been shown to be a useful protease inhibitor in HIV-1 infected adults and is increasingly used as first-line PI because of a good tolerability and toxicity profile.
Whilst darunavir is virologically effective and well-tolerated in children [4, 8] , combination ART is a lifelong treatment so it is important to assess how each drug within a class can be used to maximise the overall benefit.
We have shown that resistance to darunavir is extremely rare in PI-naïve children. This finding suggests that with the introduction of paediatric formulations, darunavir could be of potential use as a first-line PI instead of LPV/r in children aged ≥3 years.
DRV/r is increasingly being used first-line in adults, and trials are also evaluating DRV/r in combination with an integrase inhibitor as a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (NEAT-001, NCT01066962). However, currently darunavir and ritonavir are separate formulations, meaning that children either have to take ritonavir as a syrup which has poor palatability, or swallow a large 100mg tablet, which cannot be crushed or split. If tablets are used rather than lower doses of syrup for tolerability reasons, then plasma levels of darunavir may also be higher. Experience to date suggests that major and/or treatment-limiting toxicities for darunavir are rare [1] [2] [3] [4] .
In our study the prevalence of DRV RAMs was also low in those whose only previous PI exposure was LPV/r, the current first choice PI. It was higher in those with exposure to PIs other than LPV/r and this observed increase is unlikely to have been solely due to virological failure on other PIs, as these effects were observed independently. We also saw more resistance with increasing time, as well as with higher levels of viraemia, on PIs. However, despite these significant effects, only 2 (1%) PI-experienced children had ≥3 IAS DRV RAMs and 6 (3%) had intermediate level resistance using the Stanford algorithm, suggesting that DRV
≥3 IAS DRV RAMs or Stanford intermediate level resistance had been on multiple PIs
(nelfinavir, amprenavir, indinavir, ritonavir, saquinavir, and tipranavir, now less favoured treatment options) for at least 3 years and none had any significant period of virological suppression on a PI. Therefore, darunavir could also be of use as a second-line PI regimen in children with intolerance to prior PIs even if the viral load has not been continuously suppressed.
In conclusion, we found negligible DRV resistance in PI-naive children, and in those with PIexperience the prevalence of resistance to darunavir was also extremely low. Therefore darunavir/ritonavir should be considered as a first PI treatment option in children and it could also be a very useful PI in a second-line regimen. 
Any Stanford mutation 1 (0.2) 1 (1) 8
1 Stanford mutation 1 (0.2) 1 (1) 7* 
Data are no. (%) of patients. * Two children had one IAS DRV RAM and one had two † Had two IAS DRV RAMs ** One child had one DRV RAM † † 4 patients had two IAS DRV RAMs
